about
The zinc finger domain of Wilms' tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cellsNew insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomasStructure of a TCR-Mimic Antibody with Target Predicts Pharmacogenetics.WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia.WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase.Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantationWT1 promotes cell proliferation in non-small cell lung cancer cell lines through up-regulating cyclin D1 and p-pRb in vitro and in vivo.Facilitating matched pairing and expression of TCR chains introduced into human T cells.Wilms' tumor 1 silencing decreases the viability and chemoresistance of glioblastoma cells in vitro: a potential role for IGF-1R de-repressionActivation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities.Wilms' tumour: connecting tumorigenesis and organ development in the kidney.Antigen-specific cellular immunotherapy of leukemia.Interactive diagnostics in the indication to allogeneic SCT in AML.Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.Promising role of reduced-toxicity hematopoietic stem cell transplantation (PART-I).Therapies currently in Phase II trials for malignant pleural mesothelioma.WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy.GATA-1 and GATA-2 binding to 3' enhancer of WT1 gene is essential for its transcription in acute leukemia and solid tumor cell lines.An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules.Role of WT1-ZNF224 interaction in the expression of apoptosis-regulating genes.Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study.Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.Curcumin inhibits WT1 gene expression in human leukemic K562 cells.Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1.Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1).The WT1 Wilms' tumor suppressor gene is a downstream target for insulin-like growth factor-I (IGF-I) action in PC12 cells.A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma.Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning.High WT1 mRNA expression after induction chemotherapy and FLT3-ITD have prognostic impact in pediatric acute myeloid leukemia: a study of the Japanese Childhood AML Cooperative Study Group.The Wilms' tumor gene-1 is a prognostic factor in myelodysplastic syndrome: a meta analysis.
P2860
Q21195233-300D0607-82A4-4095-B5AB-305010A82C6CQ26859274-D3C254AB-D77D-40D3-B37E-F8E644B16161Q30382749-2BE844A5-6190-4105-AAD2-6644B1D84E56Q33284886-E6F562AA-4B9C-4A8C-B4A8-8F711616551BQ33814519-C3A77D1F-09CA-4DF4-853A-B674A0AABEC1Q34022415-AF15E753-57EB-495F-ABEE-C79C2665164AQ34861985-FE7E091F-5DC3-4FBA-8EAF-6FD8F82FEC20Q34924201-450CA812-2D79-4D3F-B663-D47CF18D3130Q35750844-8EA71D40-3568-4C22-B999-983464DABBB7Q35751162-006CEE61-A21B-48CF-8D96-1B469E2D81F2Q35850673-BE31B19B-A9D2-43BE-A0FB-680B8DC52619Q36234726-1203ECC2-DD58-49B8-9553-41914D862B4AQ36240201-E4FB82EC-8B40-45D1-B605-EA15FB49E021Q37442649-138DF99A-68F4-4E34-99A3-5DB1946675F1Q37659113-2FE54399-6B23-425E-80EC-74CB986A784CQ37731754-8B108CED-5169-4597-80B7-8D68BA58A9C4Q38029953-D36E3B6D-7D72-4811-920E-ACEAD7FA0A73Q38118385-75096971-32A6-4F2B-9A0C-37BFDA37BB41Q38187457-0DE7AC0F-A97F-427C-8A1D-927CD527D1B5Q38356667-98AAF1B6-5ACB-428A-BEF4-5620B7718CB0Q38739446-1BB062BB-BEA8-4351-B7F2-A3F02C40CA9DQ39202260-23763440-E53B-430D-AB57-AB39CC4B5CDEQ39992358-A1E1E4CD-408E-4436-97EB-5C4838012654Q40035267-B013BC5D-025F-4E8B-9649-7748E9DF21E2Q40313896-8B24C08A-B036-4C13-9F90-A4CFF8785F6FQ47096729-48ED701E-AFF6-4516-97DE-DC2552DFD4E4Q51932956-1509246E-75B7-4E8C-860E-EC50C6DBCD95Q53605122-728FE854-3FF7-4B29-ACEA-CBF5ACF05DB6Q54046740-E3E6BE5C-698F-4E04-A69A-D8A18D65CE75Q54398542-B0F87765-DBE7-4042-B43F-EA67B30E76DDQ54488953-F7D9213B-3478-40BF-A08F-798F20ED55C6Q55025570-DE89912B-5B65-4502-803A-DC87E360D066
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Wilms' tumour gene 1 (WT1) in human neoplasia.
@en
type
label
Wilms' tumour gene 1 (WT1) in human neoplasia.
@en
prefLabel
Wilms' tumour gene 1 (WT1) in human neoplasia.
@en
P2093
P2860
P356
P1433
P1476
Wilms' tumour gene 1 (WT1) in human neoplasia.
@en
P2093
Keilholz U
Menssen HD
Scheibenbogen C
Sugiyama H
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403817
P577
2005-08-01T00:00:00Z
P5875
P6179
1028866376